Search

El objetivo de este trabajo es presentar los resultados obtenidos al aplicar la técnica de matriz de riesgo, con la aplicación SEVRRA, en braquiterapia, y además las precauciones que se deben tomar en su aplicación y en la interpretación de los resultados. Para este fin se realizó el análisis de riesgo de una instalación de braquiterapia de alta tasa de dosis utilizando el software SEVRRA y con una herramienta desarrollada en base en el método de matriz de riesgo en una hoja de cálculo. Los resultados del segundo cribado mostraron discrepancias entre el perfil de riesgo obtenido con la aplicación SEVRRA y la herramienta propia. El porcentaje de sucesos iniciadores con riesgo alto con la aplicación SEVRRA fue de 6 %, y con la herramienta propia de 14 %. Luego de un análisis de cada suceso se observó que las discrepancias se deben a que la ponderación de la robustez de las barreras de seguridad en SEVRRA es inconsistente con las definidas en la técnica de matriz de riesgo. Estos resultados tienen profundas implicaciones en función de la aceptabilidad del riesgo planteada en la metodología. Adicionalmente, se encontró que la metodología de matriz de riesgo no tiene en cuenta los riesgos inherentes a la práctica. A pesar de las inconsistencias observadas, se reconoce el potencial de la herramienta SEVRRA para la evaluación de riesgo de instalaciones radiactivas, por ser de fácil uso; sin embargo, se recomienda la revisión de la robustez de algunas barreras, con el fin de obtener el perfil de riesgo de acuerdo con la metodología. De esta forma en base a los resultados, se podrán priorizar las medidas que deben adoptarse para garantizar la seguridad radiológica de las instalaciones.

Purposes: We analyzed patient, tumor and dosimetric characteristics of subjects in a Spanish population diagnosed with uveal melanoma treated with iodine 125 (I125) episcleral brachytherapy, who presented with post-treatment loss of useful visual acuity and global evolution of visual acuity. Methods: A single historic observational cohort study was undertaken. Patients with uveal melanoma were recruited between September 1995 and June 2015. Clinical, tumor and dosimetric data collection and visual acuity evaluations were performed under everyday practice conditions based on a useful visual acuity >0.1 on the decimal scale. The baseline analysis was performed using descriptive and survival analyses according to Kaplan-Meier curves. Results: A total of 286 of the 665 patients diagnosed with uveal melanoma received episcleral brachytherapy, and 198 were included in the study. The mean follow-up time was 75.3 months (95% CI = 68.0-82.6). Patients with post-treatment useful visual acuity loss (n=94, 47%) presented the following characteristics: visual symptoms (n=80, p-value = 0.001); iris color (brown n=33, hazel green n=49, p-value = 0.047); Collaborative Ocular Melanoma Study size (medium n=80, p-value = 0.159); tumor, node, metastasis stage (T2: n=38, T3: n=38, p=0.012); shape (nodular n=67, mushroom-shaped n=26, p=0.001); posterior pole involvement (n=47, p=0.04); recurrence (n=10, p=0.001); and dose administered in the fovea, optic nerve and center of the eye (p

Purpose To evaluate the preliminary results of the use of 68 Gy EQD2(α/β=3 Gy) as a dose limit to the lowest dose in the most exposed 2 cm3 of the vagina in order to reduce G2 late vaginal problems in postoperative endometrial carcinoma (EC). Methods From November 2016 to October 2019, 69 postoperative EC patients receiving vaginal brachytherapy (VBT) ± external beam radiotherapy (EBRT) were prospectively analyzed. The median EBRT dose was 45 Gy (range: 44–50.4 Gy), 1.8−2 Gy/day, 5 fractions(Fr)/week. VBT was administered with the following schedule: 1Fr of 7 Gy after EBRT and 2 daily Fr × 7.5 Gy in exclusive VBT. The dose was prescribed at 0.5 cm from the applicator surface with an active length of 2.5 cm; 56 patients were treated with vaginal cylinders (49–3.5 cm, 6–3 cm, and 1–2.5 cm) and 13 with the colpostat technique. The overall VBT dose was adjusted to meet the vaginal restriction of (α/β=3 Gy) at 2 cm3. Late toxicity was prospectively assessed using RTOG scores for bladder and rectum, and the objective LENT-SOMA criteria for vagina. Results With a median follow-up of 31.0 months, no vaginal-cuff recurrences were found. Late toxicity: only 1G1(1.4%) rectal toxicity; 21G1(30.4%) and 3G2(4.3%) vaginal complications. Only one (1.4%) of 3 G2 manifested as vaginal shortening. Conclusions In postoperative EC patients treated with VBT, only one developed G2 vaginal stenosis with the use of 68 Gy EQD2(α/β=3 Gy) as a dose constraint. These preliminary results seem to indicate the value of this dose limit for reducing G2 vaginal stenosis. Nonetheless, these findings should be confirmed in a larger number of patients with longer follow-up.

Purpose: Long-term comparative effectiveness research on localized prostate cancer treatments is scarce, and evidence is lacking especially for brachytherapy. The aim of this study was to assess the long-term impact of the side effects of radical prostatectomy, brachytherapy, and external radiation therapy on patients with localized prostate cancer at 10 years, using propensity score analyses. Methods and Materials: This was a prospective observational study of a cohort of men who received a diagnosis of clinically localized prostate cancer (clinical stage T1 or T2, low and intermediate risk group) and were treated with radical prostatectomy (n = 139), brachytherapy (n = 317), or external radiation therapy (n = 194). Treatment decisions were jointly made by patients and physicians. Patient-reported outcome (PRO) evaluation included the Expanded Prostate Cancer Index Composite and Short Form-36, administered centrally by telephone interviews before and annually after treatment. The Expanded Prostate Cancer Index Composite covers urinary, bowel, sexual, and hormonal domains. To assess PRO changes over time, while accounting for correlation among repeated measures, generalized estimating equation models adjusted by propensity scores were constructed. Results: The PRO completion rate at 10 years was 85.8%. Generalized estimating equation models showed that the pattern of radical prostatectomy side effects, with substantial urinary incontinence and sexual dysfunction, remained until 10 years after treatment (standard deviation [SD], -1.1 and -1.3, respectively). Brachytherapy produced late deterioration in urinary continence (SD, -0.4) and sexual function (SD, -0.9) that appeared midterm, but the differences from radical prostatectomy remained statistically significant at 10 years (P < .001 after adjusting by propensity score). External radiation therapy showed similar results to brachytherapy, but with bowel bother (SD, -0.3). Conclusions: Although late deterioration in radiation therapy groups attenuated differences from radical prostatectomy, relevant PRO differences still remained after 10 years. Our findings support that brachytherapy is the treatment option that causes the least impact on PROs; it is therefore an alternative to be considered when making evidence-based decisions on localized prostate cancer treatment. (C) 2021 The Authors. Published by Elsevier Inc.

Objective: to analyze the sociodemographic and clinical profile of women with gynecological cancer in brachytherapy. Method: a cross-sectional study including records of 1,930 visits of women in brachytherapy assisted between 2006-2016 in Santa Catarina (Brazil). Collection was performed in 2019, in an institutional bank, submitted to frequency measurements, chi-square test, 95% confidence intervals, significance level of 0.05. Results: women aged 40-59 years (47.2%), white (93.3%); with elementary school (65%); cervical cancer (78.5%); stages II-III (73.3%) figured prominently. In the comparison of staging proportions in the topography variable, a higher proportion of malignant neoplasm of cervix uteri unspecified in the grouped III-IV staging (84.6%). Conclusion: the profile analysis shows the need for screening and health education for prevention and/or early detection of gynecological cancers and training of nurses specialized in radiotherapy to care for women’s health. RESUMEN Objetivo: analizar el perfil sociodemográfico y clínico de mujeres con cáncer ginecológico en braquiterapia. Método: estudio transversal que incluyó registros de 1.930 visitas de mujeres en braquiterapia asistidas entre 2006-2016 en Santa Catarina (Brasil). La recolección se realizóen 2019, en un banco institucional, sometida a medidas de frecuencia, pruebachi-cuadrado, intervalos de confianza al 95%, nivel de significancia de 0,05. Resultados: predominaron las mujeres entre 40-59 años (47,2%), blancas (93,3%); con educación primaria (65%); cáncer de cuello uterino (78,5%); en estadios II-III (73,3%). Al comparar las proporciones de estadificación en la variable topografía, encontramos una mayor proporción de malignidad cervical no especificada la estadificación agrupada III-IV (84,6%). Conclusión: el análisis del perfil muestra la necesidad de cribado y educación sanitaria para la prevención y/o detección temprana de cánceres ginecológicos y la formación de enfermeras especializadas en radioterapia para el cuidado de la salud de la mujer. RESUMO Objetivo: analisar o perfil sociodemográfico e clínico de mulheres com câncer ginecológico em braquiterapia. Método: estudo transversal incluindo registros de 1.930 atendimentos de mulheres em braquiterapia assistidas entre 2006-2016 em Santa Catarina (Brasil). Coleta foi realizada em 2019, em banco institucional, submetida às medidas de frequência, Teste Qui-Quadrado, intervalos de 95% de confiança, nível de significância de 0,05. Resultados: predominaram as mulheres entre 40-59 anos (47,2%),brancas (93,3%); com ensino fundamental (65%); câncer do colo do útero (78,5%); nos estádios II-III (73,3%). Na comparação das proporções dos estadiamentos na variável topografia, encontrou-se uma maior proporção da neoplasia maligna do colo do útero não especificada nos estadiamentos III-IV agrupados (84,6%). Conclusão: a análise do perfil mostra a necessidade do rastreamento e educação em saúde para prevenção e/ou detecção precoce dos cânceres ginecológicos e a formação de enfermeiros especialistas em radioterapia para atendimento da saúde da mulher.

Purpose Breast-conserving treatment (BCT) have emerged as an alternative to mastectomy in patients with ipsilateral breast tumor recurrence (IBTR). We evaluated survival outcomes and treatment-related toxicity in a series of 40 patients with IBTR, who underwent tumorectomy plus interstitial brachytherapy (APBI) as a salvage treatment. Material and methods Retrospective analysis included 40 patients diagnosed with IBTR and treated with intraoperative (26 patients) or post-operative (14 patients) multicatheter brachytherapy for APBI at our institution between June 2002 and October 2017. We assessed cosmesis, toxicity, overall survival (OS), and cancer-specific survival (CSS). Results Tumorectomy was performed in all cases, including intraoperative tumor margin assessment and sentinel node biopsy. Median age was 65 years (range, 41-92). The total prescribed dose was 32 Gy (8 fractions) in 19 patients and 34 Gy (10 fractions) in 20 patients. One elderly patient (age 92) received a single fraction of 16 Gy. Median follow-up was 61.5 months (range, 6-153). A median of 14 tubes were inserted. Mean treated V100 was 115 cc. Two patients developed a second relapse at 3 and 5 years after salvage treatment: one patient underwent salvage mastectomy and remains alive 10 years after brachytherapy, and the second one developed both local relapse and bone metastasis. The disease is stable at present. Five-year OS and CSS rates were 85.3% and 97.5%, respectively. Two patients died from cancer-related causes. Acute and late toxicity rates were low; seven patients developed acute infectious mastitis. Late fibrosis > grade 3 and late mastitis were observed in 14 and 6 cases, respectively. Conclusions Second BCT with APBI as a salvage treatment in ipsilateral breast recurrence achieves good local disease control, with a satisfactory toxicity profile compared to mastectomy. This approach seems to be safe and effective, although more data from randomized trials are needed.

Made available in DSpace on 2020-12-12T01:21:27Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-07-01 Purpose: The purpose of this study was to compare the treatment outcomes of partial-breast irradiation (PBI) versus whole-breast radiotherapy (WBRT) in early breast cancer. Methods and Materials: Eligible randomized clinical trials were identified on Medline, Embase, the Cochrane Library, and the proceedings of annual meetings through December 2019. A meta-analysis for local recurrence (LR), overall mortality (OM), and non-breast cancer mortality (NBCM) was conducted. When possible, the outcomes were calculated for 5, 7, and 10 years of followup. A subgroup analysis by PBI technique (brachytherapy [BT], external beam radiotherapy [EBRT], intraoperative radiotherapy [IORT], and mixed) was performed. A p value < 0.05 was considered significant. Results: Eleven randomized clinical trials with a total of 14,436 patients (7186 PBI vs. 7250 WBRT) were included in the meta-analysis. The odds ratio (OR) for LR in 5 y was 1.46 (95% CI 1.15–2, p = 0.024) for PBI. In the subgroup analysis, no significant difference for LR was observed between PBI and WBRT using BT (p = 0.51), EBRT (p = 0.25), or mixed techniques (p = 0.89). The only subgroup with statistical difference was IORT 3.1 (95% CI 1.2–7.6, p = 0.014). No significant difference in LR was observed with 7 and 10 years among the groups. The OM had no difference at 5, 7, and 10 years of followup for any subgroup. A nonsignificant difference was observed comparing PBI with WBRT for NBCM OR = 1.24 (95% CI 0.98–1.57, p = 0.07). The rates of cardiac death, contralateral breast cancer, and development of second tumor were not significant. Conclusions: The LR with PBI is low and similar to WBRT in selected early breast cancer with a longer followup. The subgroup analysis detected a significant difference for LR associated with IORT and no significant difference for BT and EBRT. Our results confirm a nonsignificant difference for OM and NBCM between PBI and WBRT. Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP) Bioscience Institute of University of State from Sao Paulo (UNESP) Faculdade de Medicina de Ribeirão Preto Bioscience Institute of University of State from Sao Paulo (UNESP)

Purpose: Skin cancer is the most common tumor in the population. There are different therapeutic modalities. Brachytherapy is one of the techniques used, in which it is necessary to build customized moulds for some patients. Currently, these moulds are made by hand using rudimentary techniques. We present a new procedure based on 3D printing and the analysis of the clinical workflow. Material and methods: Moulds can be made either by hand or by automated 3D printing. For making moulds by hand, a patient’s alginate negative is created and, from that, the gypsum cast and customized moulds are made by hand from the patient’s negative template. The new process is based on 3D printing. The first step is to take a 3D scan of the surface of the patient and then, 3D modelling software is used to obtain an accurate anatomical reconstruction of the treatment area. We present the clinical workflow using 3D scanning and printing technology, comparing its costs with the usual custom handmade mould protocol. Results: The time spent for the new process is 6.25 hours, in contrast to the time spent for the conventional process, which is 9.5 hours. We found a 34% reduction in time required to create a mould for brachytherapy treatment. The labor cost of the conventional process is 211.5 vs. 152.5 hours, so the reduction is 59 hours. There is also a 49.5% reduction in the financial costs, mostly due to lack of need of a computed tomography (CT) scan of the gypsum and the mould. 3D scanning and printing offers financial benefits and reduces the clinical workload. Conclusions : As the present project demonstrates, through the application of 3D printing technologies, the costs and time spent during the process in the clinical workload in brachytherapy treatment are reduced. Overall, 3D printing is a promising technique for brachytherapy that might be well received in the community.

RESUMO Objetivo: validar os conteúdos de um instrumento elaborado para avaliação e classificação da estenose vaginal pós-braquiterapia para aplicação por enfermeiros. Método: estudo metodológico que incluiu dez enfermeiros experts em braquiterapia. A coleta de dados foi realizada entre dezembro de 2015 a abril de 2016 e ocorreu com a aplicação de formulário disponibilizado aos experts via ferramenta do Google Drive/Microsoft® em três rodadas de validação, conduzida pela Técnica Delphi; 12 conteúdos foram avaliados. A análise dos dados ocorreu pelo cálculo do Índice de Validade de Conteúdo - IVC. Resultados: na primeira rodada, o uso de absorventes íntimos (tampões) foi excluído (IVC=0,4), outros conteúdos foram ajustados, bem como a aparência do instrumento, de acordo com as recomendações dos experts. Os conteúdos na terceira rodada de avaliação atingiram o IVC=1. Conclusão: a validação de conteúdo de instrumento padroniza a técnica, consequentemente, incrementa e qualifica a prática clínica e o desenvolvimento de pesquisas. RESUMEN Objetivo: prever el síndrome metabólico en adolescentes a partir de indicadores antropométricos por análisis de sensibilidad y especificidad de los puntos de corte. Método: estudio transversal y descriptivo en una muestra estratificada de 716 adolescentes de 10 a 19 años seleccionados por muestreo aleatorio simple en 30 escuelas públicas, municipales y estatales localizadas en Picos, Piauí, en la Región Noreste del Brasil. La obtención de datos se realizó en el período de Agosto hasta Diciembre del 2014 y en Marzo del 2015. Se investigaron los factores índice de masa corporal y el índice de conicidad. El síndrome metabólico se identificó a partir de los criterios adaptados para la edad. Resultados: se observó la prevalencia de estudiantes del sexo femenino (61,3%) y la prevalencia del síndrome metabólico fue del 3,2%. El área sobre la curva de Características de Operación del Receptor mostró que el índice de masa corporal y el índice de conicidad se mostraron eficientes para la previsión del síndrome metabólico tanto en la muestra total como en la estratificación por sexo. Conclusión: los indicadores antropométricos índice de masa corporal e índice de conicidad fueron buenos previsores del síndrome metabólico en esa población. ABSTRACT Objective: to validate the content of an instrument prepared for evaluation and classification of vaginal stenosis after brachytherapy for its application by nurses. Method: a methodological study that included ten nurses who are experts in brachytherapy. The data collection was performed between December 2015 and April 2016 and it was carried out through the application form made available to experts via the Google Drive/Microsoft® tool in three validation rounds, conducted by the Delphi Technique; 12 contents were evaluated. The data analysis was performed by calculating the Content Validity Index - CVI. Results: in the first round, the use of intimate tampons was excluded (CVI=0.4), other contents have been adjusted, as well as the appearance of the instrument, according to the experts’ recommendations. The content in the third round of evaluation reached the CVI=1. Conclusion: the instrument content validation standardizes the technique; consequently, it increases and qualifies the clinical practice and research development.

Chronic radiation proctopathy is a frequent complication after both pelvic external radiation therapy and brachytherapy and most commonly presents as rectal bleeding. Deep rectal ulcers and fistulae are much rarer and more clinically challenging consequences. We present the case of a 72-year-old male with a history of prostate adenocarcinoma treated with brachytherapy, who was referred to our institution due to a deep painful rectal ulcer refractory to medical treatment. The ulcer presented shortly after a haemorrhoid elastic band ligation and progressed to rectourethral fistulisation despite both faecal and urinary diversion. Our case demonstrates the importance of favouring a conservative approach when dealing with an irradiated rectum. A proctopatia rádica crónica é uma complicação frequente tanto após radioterapia pélvica externa como após braquiterapia e a apresentação mais comum são rectorragias. Úlceras rectais profundas e fístulas são consequências muito mais raras e clinicamente mais difíceis. Apresentamos o caso de um homem de 72 anos, com um adenocarnicoma prostático tratado com braquiterapia, referenciado à nossa instituição por uma úlcera rectal profunda e dolorosa, refractária a tratamento médico. A úlcera surgiu pouco tempo após a laqueação elástica de uma hemorróida e progrediu para uma fístula rectouretral apesar de derivação fecal e urinária. Este caso ilustra a necessidade de uma abordagem conservadora ao lidar com mucosa rectal irradiada.

SUMMARY Cervical cancer is the most common gynecological cancer in Brazil. Among women, it is the second most frequent, second only to breast cancer. It is the fourth leading cause of cancer death in the country, with estimated 15,590 new cases (2014) and 5,430 deaths (2013). In order to update information to improve outcomes, reduce morbidity and optimize the treatment of this cancer, this article will address the advancement of knowledge on cervical cancer. The topics covered include the role of surgery in different stages, treatment of locally advanced carcinomas, fertility preservation, the role of the sentinel lymph node technique, indications and techniques of radiotherapy and chemotherapy, and some special situations. RESUMO O câncer de colo uterino é o câncer ginecológico mais frequente em nosso meio. Entre as mulheres, é o segundo mais frequente, atrás apenas do câncer de mama. É a quarta causa de morte por câncer no Brasil, com estimativa de 15.590 casos novos (2014) e com 5.430 mortes (2013). No intuito de atualizar informações para a melhora do prognóstico, redução da morbidade e otimização do tratamento dessa neoplasia, serão abordados neste artigo os avanços nos conhecimentos sobre o câncer cervical. Entre os temas apresentados, estão o papel da cirurgia nos diferentes estádios, o tratamento dos carcinomas localmente avançados, a preservação da fertilidade, o papel da técnica do linfonodo sentinela, indicações e técnicas da radio e quimioterapia, além de situações especiais.

Endoesophageal brachytherapy is a useful technique for the palliative treatment of dysphagia in advanced oesophageal cancer. This technique offers good results on dysphagia control and quality of life. We report the case of a patient treated with this technique presenting complete response to the dysphagia. We describe endoesophageal brachyterapy technique and we comment on the literature.

For tumors of the lower third of the rectum, the only safe surgical procedure is abdominal-perineal resection. High-dose-rate interstitial brachytherapy is a promising treatment for local recurrence of previously irradiated lower rectal cancer, due to the extremely high concentrated dose delivered to the tumor and the sparing of normal tissue, when compared with a course of external beam radiation therapy.

Neste estudo, busquei compreender as vivências de mulheres portadoras de câncer uterino antes de submeterem ao tratamento braquiterápico. Trata-se de uma pesquisa qualitativa embasada na fenomenologia existencial de Martin Heidegger que possibilitou a apreensão dos momentos vividos por esses seres. Para participar dessa pesquisa, procurei por mulheres que haviam iniciado algum tipo de tratamento para câncer uterino. Selecionei aquelas que se submeteram à radioterapia em uma clínica de radioterapia situada no noroeste do Paraná, e, a posteriori, seriam submetidas à braquiterapia no período compreendido entre os meses de abril a maio de 2006. Foram entrevistadas quatro mulheres em um hospital especialista em oncologia no norte do Paraná, antes de iniciarem a braquiterapia. Para buscar os discursos dos sujeitos, utilizei a seguinte questão norteadora: “O que você sente antes de vivenciar a braquiterapia”? Da interpretação emergiram três temáticas: O ser-com-o-outro inautêntico no convívio do hospital; angústia ante o desconhecimento do tratamento; religiosidade: o caminho da esperança. Os resultados obtidos revelam a importância do cuidado holístico ao Ser que vivencia esta facticidade, pois, muitas vezes, a subjetividade do cuidado fica absorvida pela massificação das regras e normas institucionais.

Context: High-dose rate brachytherapy (HDR-BT) is an increasingly popular treatment for patients with localized prostate cancer (PC). Objective: To assess the safety and efficacy of HDR-BT as monotherapy in PC. Acquisition of evidence: A systematic literature review was conducted through searches on MEDLINE (PubMed), Cochrane Library, CDR, ClinicalTrials and EuroScan. We assessed safety and efficacy indicators. Summary of the evidence: We selected 2 reviews and 12 uncontrolled studies, included in these 2 reviews. In terms of efficacy, local control in 6 studies was 97–100%. The biochemical progression-free survival varied as follows: 85–100% for low risk and 79–92% for high risk. Survival free of metastases was >95% at 8 years, except in one study where the survival rate was 87% at 5 years. The overall survival was ≥95% in 8 studies. In terms of safety, most of the studies recorded acute and long-term genitourinary and gastrointestinal complications, especially grade ≥2. Only 3 studies found grade 4 complications. All studies, except for one without complications, observed genitourinary complications that were more frequent and severe than the gastrointestinal complications. Two studies assessed the quality of life and showed an initial reduction in various domains and subsequent partial or total recovery, except in the sexual domain. Conclusions: HDR-BT is effective as monotherapy, especially in cases of low to intermediate risk. There is insufficient information on high-risk patients. The short to medium-term toxicity was acceptable. Further research needs to be funded to provide more information on the long-term safety and efficacy of this treatment. Contexto: La braquiterapia con alta tasa de dosis (HDR-BT) es un tratamiento de uso creciente en pacientes con cáncer de próstata (CP) localizado. Objetivo: Evaluar la eficacia y seguridad de HDR-BT como monoterapia en CP. Adquisición de evidencia: Revisión sistemática de la literatura mediante búsqueda en MEDLINE (PubMed), Cochrane Library, CDR, Clinicaltrials y EuroScan. Se evaluaron indicadores de eficacia y de seguridad. Síntesis de evidencia: Fueron seleccionadas 2 revisiones y 12 estudios no controlados, incluidos en estas 2 revisiones. En términos de eficacia, el control local en 6 estudios es 97-100%. La supervivencia libre de progresión bioquímica varía: 85-100% en riesgo bajo y 79-92% en riesgo alto. La supervivencia libre de metástasis es >95% a 8 años, salvo en un estudio que es 87% a 5 años. La supervivencia global es ≥95% en 8 estudios. En relación con la seguridad, la mayoría de los estudios recogen complicaciones genitourinarias y gastrointestinales agudas y a largo plazo, especialmente de grado ≥2. Solo 3 estudios encuentran complicaciones grado 4. Excepto uno (sin complicaciones), en los 11 restantes las complicaciones complicaciones genitourinarias son más frecuentes y más graves que las gastrointestinales. Dos estudios evalúan la calidad de vida y muestran un descenso inicial en distintos dominios y posterior recuperación parcial o total, salvo en la esfera sexual. Conclusiones: La HDR-RT como monoterapia es eficaz, especialmente en riesgo bajo e intermedio. No existe suficiente información en pacientes de riesgo alto. La toxicidad a corto-medio plazo es aceptable. Consideramos necesario potenciar la investigación que aporte más información sobre eficacia y seguridad a largo plazo de este tratamiento. Sin financiación 1.260 JCR (2017) Q4, 61/76 Urology and Nephrology UEM

Purpose RayStretch is a simple algorithm proposed for heterogeneity corrections in low-dose–rate brachytherapy. It is built on top of TG-43 consensus data, and it has been validated with Monte Carlo (MC) simulations. In this study, we take a real clinical prostate implant with 71 125I seeds as reference and we apply RayStretch to analyze its performance in worst-case scenarios. Methods and Materials To do so, we design two cases where large calcifications are located in the prostate lobules. RayStretch resilience under various calcification density values is also explored. Comparisons against MC calculations are performed. Results Dose–volume histogram–related parameters like prostate D90, rectum D2cc, or urethra D10 obtained with RayStretch agree within a few percent with the detailed MC results for all cases considered. Conclusions The robustness and compatibility of RayStretch with commercial treatment planning systems indicate its applicability in clinical practice for dosimetric corrections in prostate calcifications. Its use during intraoperative ultrasound planning is foreseen.

This narrative review identified, in the scientific production, the methods used for evaluating and classifying vaginal stenosis in women who have undergone brachytherapy. Data collection was undertaken in July 2013 in the publications of SciELO, MEDLINE and PubMed, without time limits, and in studies cited by two scientific reviews which addressed the issue investigated here. The search protocol included the description of the method for evaluating and classifying vaginal stenosis. Comparative analysis between the findings showed there to be diversity among the methods used by different researchers. In the light of this finding, this study proposes elements for making an evaluative instrument to be applied by nurses. The standardization of the technique will help in the early detection of vaginal stenosis and in the care for women subsequent to vaginal brachytherapy. RESUMEN Revisión narrativa que identificó en los métodos de producción científicos utilizados para la evaluación y clasificación de las estenosis vaginal en mujeres después de braquiterapia vaginal. La recolección de datos se llevó a cabo en julio de 2013 en las publicaciones de la SciELO, Medline y PubMed, sin límite de tiempo, y estudios citados dos revisiones científicas que abordan el tema investigado aquí. El protocolo de búsqueda incluyó la descripción del método para la evaluación y clasificación de la estenosis vaginal. Análisis comparativo de los resultados mostró que existen diferencias entre los métodos utilizados por diferentes investigadores. Teniendo en cuenta este resultado, este estudio propone constituyentes para hacer un instrumento de evaluación para ser utilizado por las enfermeras. La estandarización de la técnica le ayudará en la detección precoz de la estenosis vaginal y atención a la mujer después de la braquiterapia vaginal. RESUMO Revisão narrativa que identificou, na produção científica, os métodos utilizados para avaliação e classificação da estenose vaginal em mulheres pós-braquiterapia. A coleta de dados foi realizada em julho 2013 nas publicações da SciELO, MEDLINE e PubMed, sem limite de tempo, e em estudos citados por duas revisões científicas que abordam a temática aqui investigada. O protocolo de busca incluiu a descrição do método para avaliação e classificação da estenose vaginal. Análise comparativa entre os achados mostrou que há diversidade entre os métodos utilizados por diferentes pesquisadores. Diante deste achado, este estudo propõe constituintes para composição de instrumento avaliativo a ser aplicado por enfermeiros. A padronização da técnica auxiliará na detecção precoce da estenose vaginal e nos cuidados à mulher pós-braquiterapia vaginal.

Background To evaluate the current status of prospective interventional clinical trials that includes brachytherapy (BT) procedures. Methods The records of 175,538 (100 %) clinical trials registered at ClinicalTrials.gov were downloaded on September 2014 and a database was established. Trials using BT as an intervention were identified for further analyses. The selected trials were manually categorized according to indication(s), BT source, applied dose rate, primary sponsor type, location, protocol initiator and funding source. We analyzed trials across 8 available trial protocol elements registered within the database. Results In total 245 clinical trials were identified, 147 with BT as primary investigated treatment modality and 98 that included BT as an optional treatment component or as part of the standard treatment. Academic centers were the most frequent protocol initiators in trials where BT was the primary investigational treatment modality (p

PURPOSE: To present experience with high dose-rate endobronchial brachytherapy in the treatment of primary tracheal tumors. PATIENTS AND METHODS: Four patients with nonresected primary tracheal tumors are presented: 2 cases of squamous cell carcinoma of the trachea, 1 of recurrent adenoid cystic carcinoma, and 1 with recurrent plasmacytoma. All received brachytherapy, alone or as a boost for primary irradiation, in 3 or 4 fractions of 7.5 Gy, calculated at a depth of 1 cm. Follow-up was considered to start from the end of brachytherapy. RESULTS: Local control was achieved in all cases at the time of first bronchoscopic evaluation. Two patients with squamous cell carcinoma died at 6th and 33rd months after brachytherapy, respectively. The first had no evidence of disease, and the latter had local recurrence. The other 2 patients were alive after 64 and 110 months of follow-up, respectively, both with no evidence of disease. Tracheal stenosis developed in these 2 cases, 22 and 69 months after brachytherapy. Tracheal stent placement was needed only for the patient with an adenoid cystic carcinoma. CONCLUSIONS: Endobronchial high dose-rate brachytherapy may be used for tracheal tumors, even as a boost for external beam irradiation, or in recurrences. Local control in 3 out of 4 patients indicates that individual cases may benefit from the treatment. Long-term survival may also be expected, mainly for tumors with adenoid cystic histology. OBJETIVO: Apresentar a experiência do tratamento de 4 pacientes com tumores primários de traquéia, não operados, submetidos à braquiterapia endobrônquica de alta taxa de dose. PACIENTES E MÉTODOS: Dois casos de carcinoma espinocelular, uma recidiva de carcinoma adenóide cístico e uma recidiva de plasmocitoma primário da traquéia. Todos receberam braquiterapia endobrônquica, exclusiva ou como reforço de dose da radioterapia externa. Foram administradas 3 ou 4 frações de 7,5 Gy cada, calculados a 1 cm de profundidade. O seguimento foi considerado a partir do término da braquiterapia. RESULTADOS: Em todos os casos houve resposta completa. Dois pacientes com carcinoma espinocelular evoluíram a óbito em 6 e 33 meses após a braquiterapia, o primeiro, sem evidência de doença e o outro por recidiva local, respectivamente. As outras 2 pacientes encontravam-se vivas após 64 e 110 meses de seguimento, sem evidência de doença. Esses 2 casos apresentaram estenose traqueal em 22 e 69 meses após a braquiterapia, sendo necessária a colocação de prótese traqueal apenas na paciente com carcinoma adenóide cístico. CONCLUSÕES: A braquiterapia endobrônquica de alta taxa de dose pode ser utilizada tanto como reforço de dose da irradiação externa quanto em recidivas. O controle local obtido em 3 de 4 pacientes indica que casos individuais podem se beneficiar desse procedimento. Sobrevida a longo prazo pode ser observada, principalmente nos casos de histologia adenóide cística.

A 68-year-old man diagnosed with choroidal melanoma (CM) in the right eye underwent treatment with episcleral brachytherapy (I125) and transpupillary thermotherapy. Ultrasound, computed tomography, and magnetic resonance imaging were performed and revealed ocular recurrence of CM. Treatment with extended enucleation was performed. Macroscopic and microscopic examinations revealed extraocular extension and malignant cells, respectively. Immunohistochemistry demonstrated tumoral Melan-A and HMB-45 expression. No cytogenic abnormalities were detected with fluorescence in situhybridization of tumor cells using probes against chromosomes 3q27 and 8q24. The patient underwent adjuvant external beam radiotherapy for treatment of residual tumor tissue. This case represents the first reported case of recurrent CM with no cytogenetic abnormalities and the absence of metastatic disease, despite a number of the poorest prognostic factors.

Purpose To demonstrate the utility of a boost with interstitial brachytherapy (BT) in breast-conserving therapy (BCT) by doing a thorough review of the literature and describing in detail our technique for delivering this boost. Material and methods Our department has been delivering the boost with interstitial BT since 1989, in most cases with rigid needles and a theoretical dosimetry. In the early years, we used low-dose-rate (LDR) with iridium-192 wires. The dose administered was 15 Gy if there were no risk factors for local relapse or 20-25 Gy in the presence of risk factors. The risk factors considered were the presence of a close margin (less than 10 mm) and an extensive intraductal component (more than 25%). After 2002, we switched to high-dose-rate (HDR); using the linear quadratic model we changed the low dose to 3 fractions of 4.5 Gy in the case of no risk factors for local relapse or to 3 fractions of 5 Gy in the presence of risk factors. Results In 79 consecutive boost patients treated in our department between 2010 and 2011, with a median follow-up of 46 months, the local control rate was 97.47%. With respect to cosmesis, fibrosis occurred in 17 cases (21.5%) and hyperpigmentation in 26 cases (32.9%). Our hospital's results are comparable in terms of local control and cosmesis to those of other authors. Conclusions This educational article describes our department's boost technique with rigid needles and comments briefly on our results using this technique in a group of consecutively treated patients in our department. A review of the literature and the published results on local control and cosmesis is also described.

OBJETIVO: Avaliar a influência no controle local de pacientes adultos e portadores de sarcoma de partes moles em extremidades e submetidos a cirurgia conservadora do membro, com braquiterapia de alta taxa de dose (BATD) como reforço para a radioterapia externa (RT). MATERIAL E MÉTODOS: Foram avaliados 16 pacientes tratados, de 1993 até 1999. A RT foi utilizada com finalidade pré ou pós-operatória (30--55 Gy) e BATD com dose de 18--36 Gy (fx 3--6 Gy BID). Com base no modelo linear quadrático calculou-se a dose efetiva biológica ("biological effective dose" - BED) para o tumor e comparou-se seu valor a dados da literatura internacional, que utiliza tratamentos com RT e braquiterapia de baixa taxa de dose (BBTD). RESULTADOS: Os valores médios e medianos da BED para os sarcomas de partes moles foram de 78,5 Gy7 e 80 Gy7. A análise univariada mostrou que a BED para o tumor, quando utilizada BATD, era semelhante ao valor de 83 Gy7 quando utilizada BBTD (p = 0,008). As taxas de controle local, sobrevida livre de doença e sobrevida global atuarial em cinco anos foram de 83,2%, 75% e 93,7%, respectivamente. CONCLUSÕES: A BATD, quando utilizada como método complementar no reforço de dose da RT no tratamento conservador dos sarcomas de partes moles, apresenta taxas de controle local equiparáveis às da literatura internacional; no entanto, estudos com número maior de pacientes e período maior de seguimento são ainda necessários para determinar o verdadeiro potencial da BATD em substituir a BBTD.

Summary Objective: this study analyzes the survival of prostate cancer patients cared for at a hospital in Minas Gerais, Brazil according to one of the following treatments: iodine-125 seed implantation or radical prostatectomy. From January 2002 to December 2005, 129 patients underwent either brachytherapy (64 patients) or surgery (65 patients). Methods: all had prostate-specific antigen, Gleason scores and clinical stage recorded prior to treatment. Biochemical relapse was defined as prostate-specific antigen (PSA)>0.4ng/mL for radical prostatectomy, and any elevation equal or higher than 2ng/mL over the PSA nadir for implanted patients. To analyze the effect of treatment on biochemical recurrence-free survival (BRFS), Kaplan-Meier curves and Cox regression were generated. Mean follow-up time was 56.1 months for patients with the implant, and 26.6 months for those operated on. BRFS in 5 years was 69% (95% CI: 58.18-77.45) for the whole cohort. Discussion: when stratified according to treatment, survival of patients who had undergone brachytherapy (79.70%) was higher to those operated on (44.30%; pvalue= 0.0056). Upon multivariate analysis, independent predictors were iPSA (HR: 2.91, 95% CI: 1,32-6,42), Gleason score (HR: 2.18, 95% CI: 1,00-4,81) and treatment modality (HR: 2.61, 95% CI: 1.18-5,75). Risk of biochemical failure was higher with surgery than brachytherapy, which may be related to the failure criteria adopted, which is different for each therapy, as well as the high rate of histological progression between preoperative prostate biopsy and surgical specimen. Conclusion: it was found that brachytherapy is a good therapeutic option for low risk prostate cancer. Resumo Introdução: este estudo avaliou a sobrevida de portadores de câncer localizado de próstata assistidos em um hospital de Minas Gerais, segundo duas modalidades terapêuticas: implante de sementes iodo-125 e prostatectomia radical. A população estudada foi de 129 pacientes tratados no período de janeiro de 2002 a dezembro de 2005 – 64 submetidos à braquiterapia e 65 à cirurgia. Métodos: todos obtiveram registro do antígeno prostático específico, escores de Gleason e estadiamento clínico anterior ao tratamento. A recidiva bioquímica foi definida como PSA > 0,4 ng/mL para prostatectomia radical, e qualquer elevação de 2 ng/mL ou mais a partir do PSA nadir para os pacientes implantados. Para análise do efeito do tratamento na sobrevida livre de recidiva bioquímica (SLRb), foram geradas curvas de Kaplan-Meier e foi efetuada regressão de Cox. O tempo mediano de seguimento foi de 56,1 meses para os implantados e de 26,6 meses para os operados. Discussão: a SLRb em 5 anos para toda coorte foi de 69% (IC95%:58,18-77,45), sendo superior para aqueles submetidos à braquiterapia (79,70%) em relação aos operados (44,30%; p-valor 0,0056). Na análise multivariada, os fatores preditores independentes foram iPSA (HR:2,91; IC95%:1,32-6,42), escore de Gleason (HR:2,18; IC95%:1,00- 4,81) e modalidade de tratamento (HR:2,61; IC95%:1,18- 5,75). O risco de falha bioquímica foi maior com a cirurgia, comparado à braquiterapia, o que pode estar relacionado ao elevado índice de progressão histológica entre biópsia prostática pré-operatória e peça cirúrgica, e pelo critério de falha adotado, distinto para cada terapêutica. Conclusão: foi possível constatar que a braquiterapia é uma boa opção terapêutica para o câncer de próstata de baixo risco.

Caso clínico: Mujer de 40 años remitida a nuestro servicio por persistencia durante meses de un cuadro de blefaritis anterior de aspecto indolente con aparición de un nódulo indurado en el párpado superior derecho filiado como chalazion refractario al tratamiento convencional, asociado a adenopatía preauricular ipsilateral. La biopsia extemporánea se informó como carcinoma sebáceo. Procedimos a la exéresis completa de dicho párpado y a su reconstrucción con injerto de mucosa palatina y colgajo glabelar. Posteriormente se practicó un vaciamiento cervical radical por la presencia de adenopatías de aspecto necrótico en diversos territorios linfáticos. Se biopsió el párpado inferior que resultó positivo para infiltración carcinomatosa que se trató mediante braquiterapia. Discusión: La precocidad en el diagnóstico de los carcinomas sebáceos palpebrales es el principal factor pronóstico. La reconstrucción en casos de necesidad de exéresis completa del párpado es factible mediante un injerto de mucosa de paladar. En nuestro caso, el carácter anaplásico y la alta agresividad de la neoplasia han supuesto un reto terapéutico. Case report: A 40-year-old woman was referred to our department due to an apparent indolent anterior blepharitis with an indurated node in her right upper eyelid, which had persisted for months. It was believed to be a chalazion associated with an ipsilateral swollen pre-aurical lymph node, which had not responded to conventional treatment. The extemporaneous biopsy was reported as sebaceous carcinoma. Complete exeresis was performed on that eyelid and it was reconstructed with a palate mucosa graft and a glabelar flap. A radical neck dissection was performed later, in order to remove the lymph nodes that appeared necrotic in several lymphatic areas. A biopsy was also performed on the lower eyelid, which was reported as positive for carcinomatous infiltration, and therefore it was treated with Curie-therapy. Discussion: The precocity in diagnosing sebaceous carcinomas of the eyelids is the main prognostic factor. The reconstruction in cases with need of complete eyelid exeresis is feasible by means of a palate mucosa graft. In our case, both the anaplastic character and the high aggressiveness of the neoplasm were a therapeutic challenge.

Objective Comparative analysis of dosimetry in intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT for treatment of brain tumors. Materials and Methods Simulations of intracavitary balloon catheter brachytherapy with I-125 and in Cf-252 brachytherapy combined with BNCT were performed with the MCNP5 code, modeling the treatment of a brain tumor on a voxel computational phantom representing a human head. Absorbed dose rates were converted into biologically weighted dose rates. Results Intracavitary balloon catheter brachytherapy with I-125 produced biologically weighted mean dose rates of 3.2E-11, 1.3E-10, 1.9E-11 and 6.9E-13 RBE.Gy.h-1.p-1.s, respectively, on the healthy tissue, on the balloon periphery and on the I 1 and I 2 tumor infiltration zones. On the other hand, Cf-252 brachytherapy combined with BNCT produced a biologically weighted mean dose rate of 5.2E-09, 2.3E-07, 8.7E-09 and 2.4E-09 RBE.Gy.h-1.p-1.s, respectively on the healthy tissue, on the target tumor and on the I 1 and I 2 infiltration zones. Conclusion Cf-252 brachytherapy combined with BNCT delivered a selective irradiation to the target tumor and to infiltration zones, while intracavitary balloon catheter brachytherapy with I-125 delivered negligible doses on the tumor infiltration zones. Objetivo Realização de uma análise dosimétrica comparativa entre a braquiterapia com balão preenchido com solução de I-125 e a braquiterapia por Cf-252 associada à BNCT, mediante simulação computacional de tratamento de tumor cerebral. Materiais e Métodos Simulações da braquiterapia com balão preenchido com solução de I-125 e da braquiterapia por Cf-252 associada à BNCT foram elaboradas no código MCNP5, modelando o tratamento de tumores cerebrais em um fantoma computacional de cabeça humana em voxels. As taxas de dose absorvidas foram convertidas em taxas de dose ponderadas e apresentadas. Resultados A braquiterapia com balão de I-125 apresentou taxa de dose ponderada média no tecido normal, na periferia do balão e nas infiltrações I 1 e I 2 de 3,2E-11, 1,3E-10, 1,9E-11 e 6,9E-13 RBE.Gy.h-1.p-1.s, respectivamente. Já a braquiterapia por Cf-252 associada à BNCT apresentou dose média no tecido normal, no tumor e nas infiltrações I 1 e I 2 de 5,2E-09, 2,3E-07, 8,7E-09 e 2,4E-09 RBE.Gy.h-1.p-1.s, respectivamente. Conclusão A braquiterapia por Cf-252 associada à BNCT produziu irradiação seletiva nas infiltrações e tumor, enquanto a braquiterapia com balão preenchido com solução de I-125 produziu doses negligenciáveis nas infiltrações.

Objective To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The results analysis was based on the definition of biochemical recurrence according to the Phoenix Consensus. Results Biochemical control was observed in 86 patients (71.7%), and biochemical recurrence, in 34 (28.3%). Mean PSAn was 0.53 ng/ml. The mean follow-up was 98 months. The patients were divided into two groups: group 1, with two year PSAn < 0.5 ng/ml after brachytherapy (74 patients; 61.7%), and group 2, with two year PSAn ≥ 0.5 ng/ml after brachytherapy (46 patients; 38.3%). Group 1 presented biochemical recurrence in 15 patients (20.3%), and group 2, in 19 patients (43.2%) (p < 0.02). The analysis of biochemical disease-free survival at seven years, stratified by the two groups, showed values of 80% and 64% (p < 0.02), respectively. Conclusion Levels of two year PSAn ≥ 0.5 ng/ml after brachytherapy are strongly correlated with a poor prognosis. This fact may help to identify patients at risk for disease recurrence. Objetivo Avaliar os valores de PSA nadir (PSAn) dois anos após braquiterapia e sua relação com a taxa de recidiva bioquímica. Materiais e Métodos Cento e vinte pacientes foram tratados no período de janeiro de 1998 a agosto de 2007. Todos os pacientes foram submetidos a braquiterapia isolada. Os resultados foram analisados com base na definição de recidiva bioquímica do Consenso Phoenix. Resultados Oitenta e seis pacientes (71,7%) tiveram controle bioquímico e 34 (28,3%) apresentaram recidiva bioquímica. O PSAn médio foi 0,53 ng/ml. O seguimento médio foi 98 meses. Os pacientes foram divididos em dois grupos: grupo 1, com PSAn < 0,5 ng/ml dois anos após a braquiterapia (74 pacientes; 61,7%), e grupo 2, com PSAn ≥ 0,5 ng/ml dois anos após a braquiterapia (46 pacientes; 38, 3%). O grupo 1 teve recidiva bioquímica em 15 pacientes (20,3%) e o grupo 2 em 19 pacientes (43,2%) (p < 0,02). A análise da sobrevida livre de doença bioquímica de sete anos, estratificada pelos dois grupos, apresentou valores de 80% e 64% (p < 0,02), respectivamente. Conclusão Os níveis de PSAn ≥ 0,5 ng/ml dois anos após a braquiterapia estão fortemente correlacionados com mau prognóstico. Este fato pode ajudar a identificar pacientes com risco de recidiva da doença.

RACIONAL: O câncer do esôfago ainda constitui neoplasia de difícil tratamento e de prognóstico muito ruim. OBJETIVO: Comparar a resposta do tratamento exclusivo com teleterapia isolada versus teleterapia associada à braquiterapia endoluminal de doentes portadores de carcinoma espinocelular avançado do esôfago. MÉTODO: Foram estudados 49 doentes portadores de carcinoma espinocelular avançado do esôfago médio em estádio clínico III (TNM). Os doentes foram divididos em dois grupos de doentes. O primeiro grupo foi submetido à teleterapia exclusiva com acelerador linear de partículas, dose média de 6000 cGy e o segundo à teleterapia na dose de 5040 cGy associada à braquiterapia endoluminal com Iridium 192 na dose de 1500 cGy. A braquiterapia foi iniciada uma a duas semanas após o término da teleterapia e dividida em três aplicações semanais de 500 cGy. Foram avaliadas as variáveis idade, sexo, raça, hábitos (tabagismo e etilismo), índice de massa corpórea (IMC), complicações com o tratamento, benefícios (melhora da dor e satisfação alimentar) e sobrevivência. RESULTADOS: Os resultados quanto a qualidade de vida (satisfação alimentar, paliação da disfagia e dor) foram melhores no grupo submetido à teleterapia associada a braquiterapia. A sobrevivência foi maior no grupo de teleterapia associada a braquiterapia. CONCLUSÃO: Apesar do índice de cura do câncer espinocelular do esôfago ser quase nulo quando tratado com irradiação isolada, esta terapêutica constitui-se em uma forma de tratamento paliativo para grande parte dos doentes em que existe contra-indicação cirúrgica. BACKGROUND: Squamous cell carcinoma of the esophagus is still a difficult tumor to treat with very poor prognosis. AIM: To compare the response to teletherapy treatment (external beam radiotherapy) alone versus teletherapy combined with brachytherapy for patients with advanced squamous cell carcinoma of the esophagus. METHODS: Were studied 49 patients with advanced squamous cell carcinoma of the esophagus on clinical stage III (TNM-1999). They were separated into two groups. The first, underwent radiation therapy alone with linear accelerator of particles, average dose of 6000 cGy and the second to external beam radiation therapy at a dose of 5040 cGy combined with brachytherapy with Iridium 192 at a dose of 1500 cGy. Brachytherapy started one to two weeks after the end of teletherapy, and it was divided into three weekly applications of 500 cGy. Age, gender, race, habits (smoking and drinking), body mass index (BMI), complications with treatment benefits (pain relief and food satisfaction) and survival were analyzed. RESULTS: The quality of life (food satisfaction, and pain palliation of dysphagia) were better in the group treated with external beam radiation therapy combined with brachytherapy. Survival was higher in the brachytherapy combined with external beam radiation therapy alone. CONCLUSION: Although the cure rate of squamous cell cancer of the esophagus is almost nil when treated with irradiation alone, this therapy is a form of palliative treatment for most patients in whom surgical contraindication exists.

Objetivo: Revisar la experiencia con implantes permanentes de semillas de I-125 en carcinoma de próstata y el resultado a los 8 años de comenzar la técnica. Material y métodos: De 2002 a 2007 hemos realizado 250 implantes con braquiterapia de baja tasa con RapidStrand® y sistema de preplanificación. La edad media fue 68 años (49-78). El PSA medio fue 7,32 (2,31-14,6), 98% T1-T2a, 96% Gleason < 6, 81% de bajo riesgo y 19% de riesgo intermedio (10 de estos últimos recibieron 46Gy de radioterapia externa). Un 42% recibieron hormonoterapia. Resultados: Con seguimiento medio de 48 meses, 14 pacientes (5,7%) tuvieron recaída bioquímica (RB). En 11 pacientes (4,5%) con teórica RB el PSA descendió espontáneamente sin tratamiento. La supervivencia actuarial sin recaída bioquímica a 5 años fue del 91% (92% bajo riesgo, 86% riesgo intermedio); 92 vs 81% en pacientes con PSA < 10 vs > 10 (p < 0,05). Hubo complicaciones rectales G2 en el 0,6%, sondaje vesical en un 6,5%; el 60% conservaron la función sexual. El V100 medio fue del 89% y el D90 143Gy. Conclusión: El resultado en carcinoma de próstata de bajo riesgo mediante semillas de Iodo-125 es muy bueno con muy pocas complicaciones. Las elevaciones de PSA deberían ser controladas antes de dar tratamiento de rescate. Introduction: We review the experience with prostate carcinoma patients treated with permanent implants of 125-I seeds and the outcome eight years after the beginning of this technique. Material and methods: From 2002 to 2007 we have performed 250 implants with LDR brachytherapy with RapidStrand® and preplanning system. Mean age was 68 (49-78). Mean PSA was 7.32 (2.31 - 14.6). T1-T2a was the stage in 98%, and Gleason < 6 in 96%. Low risk cases were 81% and intermediate risk 19% (ten of them received 46Gy EBRT). Hormonal treatment was used in 42%. Results: With a mean follow-up of 48 months, 14 patients (5.7%) showed biochemical failure (BF). Eleven patients (4.5%) with theoretical BF were observed and PSA decreased without treatment. Actuarial PSA relapse-free survival at 5 years was 91%, (92% low risk, 86% intermediate cases), and 92% vs 81% with PSA 10 (p

OBJETIVO: Este artigo mostra um procedimento de conversão de imagens de tomografia computadorizada ou de ressonância magnética em modelo de voxels tridimensional para fim de dosimetria. Este modelo é uma representação personalizada do paciente que pode ser usado na simulação, via código MCNP (Monte Carlo N-Particle), de transporte de partículas nucleares, reproduzindo o processo estocástico de interação de partículas nucleares com os tecidos humanos. MATERIAIS E MÉTODOS: O sistema computacional desenvolvido, denominado SISCODES, é uma ferramenta para planejamento computacional tridimensional de tratamentos radioterápicos ou procedimentos radiológicos. Partindo de imagens tomográficas do paciente, o plano de tratamento é modelado e simulado. São então mostradas as doses absorvidas, por meio de curvas de isodoses superpostas ao modelo. O SISCODES acopla o modelo tridimensional ao código MCNP5, que simula o protocolo de exposição à radiação ionizante. RESULTADOS: O SISCODES vem sendo utilizado no grupo de pesquisa NRI/CNPq na criação de modelos de voxels antropomórficos e antropométricos que são acoplados ao código MCNP para modelar braquiterapias e teleterapias aplicadas a tumores em pulmões, pelve, coluna, cabeça, pescoço, e outros. Os módulos atualmente desenvolvidos no SISCODES são apresentados junto com casos exemplos de planejamento radioterápico. CONCLUSÃO: O SISCODES provê de maneira rápida a criação de modelos de voxels personalizados de qualquer paciente que podem ser usados em simulações por códigos estocásticos tipo MCNP. A combinação da simulação via MCNP com um modelo personalizado do paciente traz grandes melhorias na dosimetria de tratamentos radioterápicos. OBJECTIVE: The present paper describes a procedure for conversion of computed tomography or magnetic resonance images into a three-dimensional voxel model for dosimetry purposes. Such model is a personalized representation of the patient that can be utilized in nuclear particle transport simulations by means of the MCNP (Monte Carlo N-Particle) code, reproducing the stochastic process of nuclear particles interaction with human tissues. MATERIALS AND METHODS: The developed computational system - SISCODES - is a tool designed for 3D planning of radiotherapy or radiological procedures. Based on tomographic images of the patient, the treatment plan is modeled and simulated. Then, the absorbed doses are shown by means of isodose curves superimposed on the model. The SISCODES couples the threedimensional model with the MCNP5 code, simulating the protocol of exposure to ionizing radiation. RESULTS: The SISCODES has been utilized by the NRI/CNPq in the creation of anthropomorphic and anthropometric voxel models which are coupled with the MCNP code for modeling brachytherapy and teletherapy applied to lung, pelvis, spine, head and neck tumors, among others. The current SISCODES modules are presented together with examples of cases of radiotherapy planning. CONCLUSION: The SISCODES provides a fast method to create personalized voxel models of any patient which can be used in stochastic simulations. The combination of the MCNP simulation with a personalized model of the patient increases the dosimetry accuracy in radiotherapy.

Altres ajuts: AATM/086/24/2000 Objetivo: comparar los costes de los tratamientos más establecidos para el cáncer de próstata localizado según grupos de riesgo, edad y comorbilidad, desde la perspectiva del proveedor asistencial. Métodos: comparación de costes en pacientes reclutados consecutivamente entre 2003 y 2005 en una unidad funcional de tratamiento del cáncer de próstata. La utilización de servicios hasta 6 meses después del inicio del tratamiento se obtuvo de las bases de datos hospitalarias, y los costes directos se estimaron mediante cálculo microcoste. La información sobre las características clínicas de los pacientes y los tratamientos recogió prospectivamente. Los costes se compararon mediante tests no paramétricos de comparación de medianas (Kruskall-Wallis) y un modelo semilogarítmico de regresión múltiple. Resultados: la diferencia de costes fue estadísticamente significativa: medianas de 3229.10D, 5369.00Dy 6265.60D para los pacientes tratados con radioterapia conformacional externa 3D, braquiterapia, y prostatectomía radical retro pública, respectivamente (p

Presentamos nuestra experiencia en el tratamiento de los queloides mediante resección quirúrgica y radioterapia inmediata posterior. La radioterapia transforma el queloide en un tejido hipocelular, hipovascular e hipóxico, impidiendo la excesiva migración de fibroblastos. Si se administra la dosis adecuada de radiación, se consigue un equilibrio entre la formación de cicatriz y la proliferación excesiva de tejido, evitando la formación de queloide, sin impedir la cicatrización normal. Nuestro protocolo se divide en dos fases: la primera consiste en la exéresis del queloide mediante una incisión que sigue el trayecto del mismo, con un cuidadoso cierre en dos planos siendo siempre el superficial una sutura intradérmica. La segunda fase será la radioterapia, con dos modalidades posibles de tratamiento: 1- Braquiterapia (tratamiento a corta distancia), requiere la colocación de un catéter bajo la sutura, a través del cual se introduce una fuente radiactiva, normalmente Ir192. Se emplea especialmente en heridas longitudinales. 2- Radioterapia externa con electrones de baja energía. Se emplea en heridas complejas o extensas. Generalmente, dosis de 20 Gy. en 4 fracciones de 500 cGy, ofrecen excelentes resultados con mínimas secuelas o efectos secundarios. El volumen blanco debe incluir la herida quirúrgica más un margen de 4 mm. alrededor de ella. Con este procedimiento, hemos observado unos excelentes resultados, con un índice de recidivas inferior al 4%, y una mejora en los síntomas clínicos en el 100% de los casos. Como efectos secundarios observamos telangiectasias (15,4 %) o cambios en la pigmentación cutánea (5,9%).

OBJETIVO: Analisar os resultados preliminares da braquiterapia com rutênio-106 em pacientes portadores de melanomas uveais. MATERIAIS E MÉTODOS: No período de abril de 2002 a julho de 2003, 20 pacientes com diagnóstico de melanoma uveal foram tratados com braquiterapia com rutênio-106. A dose calculada no ápice tumoral variou de 55 Gy a 100 Gy. Pacientes com lesões com altura maior que 5 mm foram submetidos a termoterapia transpupilar concomitante à colocação da placa oftálmica. RESULTADOS: Quanto à localização da lesão, esta se encontrava na coróide em 75% dos casos, na íris em 15% e no corpo ciliar em 10% dos pacientes. Com seguimento mediano de 19 meses, a sobrevida livre de progressão para a braquiterapia e para a associação com a termoterapia transpupilar foi de 69% e 87%, respectivamente. Observou-se redução significante da altura tumoral após o tratamento. Nenhum dos pacientes foi submetido a enucleação. CONCLUSÃO: Nossos resultados preliminares mostram que a braquiterapia com rutênio-106 é uma opção adequada para o tratamento conservador de melanomas uveais em termos de controle local, manutenção do globo ocular e visão útil, com índice aceitável de complicações. OBJECTIVE: To analyze the early response of uveal melanomas in patients treated with ruthenium-106 brachytherapy. MATERIALS AND METHODS: In the period between April 2002 and July 2003, 20 patients diagnosed with uveal melanoma were submitted to ruthenium-106 brachytherapy. The calculated dose delivered at the apex of the tumor ranged between 55 Gy and 100 Gy. Patients with lesions greater than 5 mm were submitted to transpupillary thermotherapy concomitantly with ophthalmic plaque insertion. RESULTS: As regards the lesions site, 75% of the lesions were located in the choroid, 15% in the iris, and the remainder 10% in the ciliary body. In a median 19-month-follow-up, the progression-free survival for brachytherapy was 69%, and 87% for associated brachytherapy and transpupillary thermotherapy. A significant tumor height reduction was observed after treatment. No patient was submitted to enucleation. CONCLUSION: Our preliminary results show that ruthenium-106 brachytherapy is an appropriate method for conservative treatment of patients with uveal melanomas in terms of local management, ocular and visual acuity preservation with an acceptable complications incidence rate.

OBJETIVO: identificar disfunções sexuais em pacientes com câncer de colo uterino submetidas à radioterapia exclusiva pela técnica de braquiterapia de alta taxa de dose. MÉTODOS: foi realizado um estudo descritivo do tipo corte transversal no período de janeiro a junho de 2004. O estudo envolveu 71 pacientes selecionadas de acordo o perfil estabelecido e que vinham sendo seguidas no ambulatório de pélvis do Hospital do Câncer de Pernambuco. Os dados foram coletados a partir de um questionário estruturado, complementado por um exame ginecológico visando investigar queixas de disfunção sexual após a radioterapia. Foi utilizado o programa estatístico Epi-Info 6.04 para processamento e análise dos dados. A análise descritiva foi feita pela média, mediana, valores máximo e mínimo. Para análise bivariada foram realizados os testes de homogeneidade marginal e McNemar, considerando um nível de significância de 5%. RESULTADOS: das complicações ginecológicas identificadas, destacam-se fibrose, estenose e atrofia vaginais (98,6, 76,1 e 71,8% dos casos, respectivamente). As disfunções sexuais identificadas foram: frigidez e falta de lubrificação, de excitação e de orgasmo, que ocorreram em 76,1% dos casos, falta de libido em 40,8% e vaginismo em 5,6% dos casos. CONCLUSÕES: as disfunções sexuais são freqüentes em pacientes com câncer do colo uterino avançado tratadas com radioterapia exclusiva utilizando o protocolo de braquiterapia de alta taxa de dose. Atenção específica deve ser dada à anamnese sexual e ao exame ginecológico durante o acompanhamento destas pacientes. PURPOSE: to identify sexual dysfunctions in patients with cancer of the uterine cervix submitted to exclusive radiotherapy, using the high dose rate (HDR) brachytherapy technique. METHODS: a descriptive transversal study from January to June of 2004. The study involved 71 selected patients who had been followed in the pelvis outpatient clinic from the Hospital do Câncer de Pernambuco and selected according to the established profile. Data were collected from a structured questionnaire, complemented by a gynecological exam aimed at investigating complaints of sexual dysfunction after the radiotherapy. Epi-Info 6.04 was the statistical program used to process and analyze the data. Descriptive analysis was done through the mean, median and range. Bivariate analysis was done through the Marginal Homogeneity and McNamara's tests, considering 5% as the level of significance. RESULTS: among the gynecological complications identified, we can highlight fibrosis, stenosis and vaginal atrophy (98.6%, 76.1% and 71.8%, respectively). The sexual dysfunctions identified were: frigidity, lack of lubrication, excitation and orgasm in 76.1% of the cases, lack of sex drive in 40.8% and vaginism in 5.6% of the cases. CONCLUSIONS: sexual dysfunctions are frequent in patients with cancer of the advanced uterine cervix treated with exclusive radiotherapy using the protocol of HDR. Specific attention should be given to the sexual anamnesis and the gynecological exam during these patients' attendance.

En la actualidad el cáncer de próstata es la neoplasia no cutánea más frecuente entre los hombres en USA, ocupando en nuestro país la segunda posición tras el cáncer de pulmón. En los últimos años se ha modificado el perfil del cáncer de próstata diagnosticado debido a la amplia difusión de la determinación del PSA. En la actualidad aproximadamente el 47% de los cánceres de próstata que se diagnostican son de bajo riesgo. En esta situación terapias mínimamente invasivas como la braquiterapia cada vez tienen una mayor aceptación en nuestro medio. Se analiza la especial cinética del PSA tras la braquiterapia y la dificultad que entraña el diagnóstico de la recidiva bioquímica tras braquiterapia realizando una revisión de la evidencia científica disponible en la literatura.

Objetive: Low dose rate (LDR) prostate brachytherapy (permanent 125I or 103Pd seeds) is an accepted treatment option for low risk prostate cancer patients. However, differences in prostate spatial location, volume and gland deformation between the images obtained during pre-planning and later on during the implant procedure prevent the pre-planned intended dose to be accurately delivered. We are reporting on a new technique based on interactive real-time dynamic intra-operative dose calculation with avoidance of post-implant CT for final dosimetry. The reasons leading us to implementing this new technique are discussed and preliminary results reported. Methods: A pre-planning TRUS for volumetric analysis is performed in all our patients prior to implantation. This TRUS accomplishes two objectives: 1) assessment of implantability of the gland, of organs at risk and anatomical considerations and 2) determination of seed activity and total number of seeds. On the day of the implant, new TRUS images from base to apex are obtained using a motorized stepper connected to the ultrasound and planning system. Each real time needle position placed on the target is identified and capture by the planning system in the true position. Once all real needle positions have been captured, dosimetry is performed intra-operatively and the physician approves the corresponding isodoses on real time. Flexible cystoscopy is then performed followed by seed placement. Each seed implanted is then identified upon withdrawing the needle using TRUS guidance. This allows real-time intra-operative dosimetric analysis, allowing for correction of under-dosed zones during implantation in an interactive dynamic manner. Peripheral loading is used. Results: We began our LDR prostate brachytherapy program on 1999. While we have treated 700 patients with LDR, the last 63 patients were treated with our real time dynamic intra-operative planning system. The median time duration for the procedure was 90 minutes. The median follow up time for these 63 patients was 20 months with a range of 10-36 months. At presentation, Stage T1c was seen in 55%, T2a in 36% and 9% as T2b. The Gleason grade was

OBJETIVO: Este estudo tem por objetivo avaliar as alterações vasculares morfológicas e morfométricas induzidas pela braquiterapia com Samário-153 (153 Sm) em coelhos hipercolesterolêmicos, com doses elevadas. MÉTODOS: Foram analisados 43 coelhos hipercolesterolêmicos, brancos, da raça New Zealand, e o total de 86 artérias ilíacas submetidas a lesão por balão de angioplastia. Divididos em três grupos: dois (GI) irradiados com as doses de 15Gy (n=14) e 60Gy (n=36) e um grupo controle (n=36). Foram realizadas avaliação histológica morfométrica e análise histológica qualitativa para análise tecidual. RESULTADOS: Foram observadas uma redução significativa da neoproliferação intimal (NPI) no GI 15 Gy (p

Objetivo: La ecografía transrectal es el método que proporciona una imagen directa de la próstata, sus límites, alteraciones estructurales y morfológicas y relaciones anatómicas. El volumen prostático es, en consecuencia, fácil de determinar, siendo el primer paso necesario para la aplicación de determinados procedimientos terapéuticos. La crioterapia y la braquiterapia prostáticas se han desarrollado en los últimos años como opciones mínimamente invasivas para el tratamiento del cáncer de próstata. La ecografía transrectal de próstata ha permitido la aplicación de estas tecnologías en la práctica diaria garantizando altos índices de eficacia y seguridad. La criocirugía es la congelación controlada de los tejidos. La ecografía transrectal de próstata es el único método capaz de reflejar en tiempo real la evolución de la crioablación prostática, permitiendo al urólogo controlar la evolución de la bola de hielo y alcanzar las estructuras anatómicas deseadas garantizando los objetivos oncológicos y disminuyendo la aparición de complicaciones y secuelas. La braquiterapia como forma de radioterapia local intraprostática necesita de cálculos volumétricos y dosimétricos exactos previos a la implantación de la fuente radioactiva en el interior de la glándula. Con ecografía transrectal de próstata se realizan cortes ecotomográficos para el cálculo del volumen y planimetría prostáticos. Una vez realizada la dosimetría y para realizar el implante de las agujas cargadas con las semillas en su lugar exacto es necesario el control con ecografía transrectal en tiempo real. Hoy en día la crioterapia y braquiterapia prostáticas serían inconcebibles sin la ecografía transrectal.

OBJECTIVE: To assess the safety and efficacy of intracoronary brachytherapy using the Beta-Cath systemTM for preventing recurrence of in-stent restenosis (ISR), by analyzing clinical, angiographic, and intracoronary ultrasound (ICUS) results. METHODS: This study assessed 30 patients with ISR in native coronary arteries who underwent balloon catheter angioplasty followed by intracoronary beta radiation with the Beta-Cath systemTM (90Sr/Y). RESULTS: The study comprised complex, extensive (18.66±4.15 mm) restenotic lesions, 77% of which were of the diffuse-proliferative type. Brachytherapy was successful in 100% of the cases. The mean radiation dose used was 20.7±2.3 Gy, released for a mean period of 3.8±2.1 minutes. On late follow-up, the in-stent minimum luminal diameter (MLD) slightly decreased (from 1.98±0.30 mm to 1.84±0.39 mm at 6 months; P=0.13), with a late loss of 0.14±0.18 mm. The intrasegmentary MLD was significantly smaller than the in-stent diameter (1.55±0.40 mm vs 1.84±0.39 mm; P=0.008), and was associated with a more significant late loss (0.40±0.29 mm vs 0.14±0.18 mm; P=0.0001). On ICUS, a mild increase of 6.8±14.3 mm3 in the neointimal tissue was observed at 6 months (P=0.19), and the percentage of volumetric obstruction increased by 4.7±7.5%. Binary restenosis and revascularization of the target vessel recurred in 17% of the cases; late occlusion associated with myocardial infarction occurred in 1 case (3%). Event-free survival was 80%. CONCLUSION: The management of in-stent restenosis with intracoronary beta radiation proved to be a safe and effective procedure, with a high rate of immediate success, representing a therapeutic option for inhibiting neointimal hyperplasia.

OBJECTIVE: To compare the rates of overall survival (OS), disease-free survival (DFS) and toxicity in different techniques of postoperative radiotherapy for stage IA endometrioid adenocarcionoma of endometrium, histological grades 1and 2. METHODS: A historical comparison between treatment regimens was performed, and 133 women with a minimum follow-up of 5 years were included. Teletherapy (TELE group), with 22 patients treated from 1988 to 1996, with a 10 MV linear accelerator, average dose 46.2 Gy. Low dose rate brachytherapy (LDRB group) was performed between 1992 and 1995, in 19 women, with an insertion of Cesium 137, at a 60 Gy dose. Fourteen women operated between 1990 and 1996 did not receive radiotherapy (NO RT group). High dose rate brachytherapy was performed in 78 patients (HDRB group), from 1996 to 2004, in five weekly 7 Gy insertions, prescribed at 0.5 cm from the vaginal cylinder. RESULTS: The 5-year disease-free survival was 94.6% for the HDRB group, 94.1% for the LDRB group, 100% for the TELE group and NO RT groups (p = 0.681). The 5-year overall survival was 86.6% for the HDRB group, 89.5% for the LDRB group and 90% for the TELE group and NO RT groups (p = 0.962). Grades 3-5 late toxicity was 5.3% in LDRB group and 27.3% for the TELE group (p < 0.001). CONCLUSION: Patients submitted to adjuvant teletherapy showed very high toxicity, which contraindicates that treatment for those patients. There may be a role for adjuvant HDRB, but randomized controlled trials are still needed to evaluate its benefit. OBJETIVO: Comparar as taxas de sobrevida global (SG), sobrevida livre de doença (DFS) e de toxicidade em diferentes técnicas de radioterapia pós-operatória para adenocarcionoma endometrioide do endométrio estádio IA, graus histológicos 1 e 2. MéTODOS: Realizou-se uma comparação histórica entre regimes de tratamento, incluindo 133 mulheres com seguimento mínimo de cinco anos. Teleterapia (grupo TELE), com 22 pacientes, de 1988 a 1996, tratadas com acelerador linear 10 MV, dose média de 46,2 Gy. Braquiterapia de baixa taxa de dose (grupo LDRB), realizada entre 1992 e 1995, em 19 mulheres, com uma inserção de Césio 137, dose de 60 Gy. Quatorze mulheres operadas entre 1990 e 1996 não receberam radioterapia (grupo NO RT). Braquiterapia de alta taxa de dose foi realizada em 78 pacientes (grupo BATD), 1996-2004, cinco inserções semanais de 7 Gy, a 0,5 cm do cilindro vaginal. RESULTADOS: A DFS em cinco anos foi de 94,6% para o grupo BATD, 94,1% para o grupo LDRB, 100% para os grupos TELE e RT (p = 0,681). A sobrevida global em cinco anos foi de 86,6% para o grupo BATD, 89,5% para o grupo LDRB e 90% para os grupos TELE e NO RT (p = 0,962). A toxicidade tardia graus 3-5 foi de 5,3% no grupo LDRB e 27,3% para o grupo TELE (p < 0,001). CONCLUSãO: Pacientes submetidos à teleterapia adjuvante apresentaram toxicidade muito elevada, o que contraindica o tratamento para essas pacientes. Pode haver um papel para a BATD adjuvante, mas estudos controlados randomizados são necessários para avaliar seu benefício.

This article is online at: http://breast-cancer-research.com/content/7/5/R690, [Introduction] Radiotherapy outcomes might be further improved by a greater understanding of the individual variations in normal tissue reactions that determine tolerance. Most published studies on radiation toxicity have been performed retrospectively. Our prospective study was launched in 1996 to measure the in vitro radiosensitivity of peripheral blood lymphocytes before treatment with radical radiotherapy in patients with breast cancer, and to assess the early and the late radiation skin side effects in the same group of patients. We prospectively recruited consecutive breast cancer patients receiving radiation therapy after breast surgery. To evaluate whether early and late side effects of radiotherapy can be predicted by the assay, a study was conducted of the association between the results of in vitro radiosensitivity tests and acute and late adverse radiation effects., [Methods] Intrinsic molecular radiosensitivity was measured by using an initial radiation-induced DNA damage assay on lymphocytes obtained from breast cancer patients before radiotherapy. Acute reactions were assessed in 108 of these patients on the last treatment day. Late morbidity was assessed after 7 years of follow-up in some of these patients. The Radiation Therapy Oncology Group (RTOG) morbidity score system was used for both assessments., [Results] Radiosensitivity values obtained using the in vitro test showed no relation with the acute or late adverse skin reactions observed. There was no evidence of a relation between acute and late normal tissue reactions assessed in the same patients. A positive relation was found between the treatment volume and both early and late side effects., [Conclusion] After radiation treatment, a number of cells containing major changes can have a long survival and disappear very slowly, becoming a chronic focus of immunological system stimulation. This stimulation can produce, in a stochastic manner, late radiation-related adverse effects of varying severity. Further research is warranted to identify the major determinants of normal tissue radiation response to make it possible to individualize treatments and improve the outcome of radiotherapy in cancer patients., This work was supported by grants from the Ministerio de Ciencia y Tecnología CICYT (SAF 2001-3533) and Ministerio de Educación y Ciencia CICYT (SAF 2004-00889). DMO and JAMG were supported by fellowships (BEFI 01/9331, BEFI 02/9029) from the Fondo de Investigaciones Sanitarias (ISCIII).